Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 374 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ¿Qué deben saber las personas con cáncer sobre el consumo de... January 11, 2022 Giving Myself the Most Time and Best Chance at Beating Cancer:... October 10, 2023 Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate... October 24, 2026 FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung... April 25, 2024 Load more HOT NEWS Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis Fatiga relacionada con el cáncer: Lo que las personas con cáncer... BRCA Gene Testing: Risks, Benefits, Costs, and Coverage Alternatives for Outdoor Foods
